Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: LEO Pharma Clear all
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

NCT03826901
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
delgocitinib
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 7, 2026, 10:19 PM EDT
Terminated No phase listed Observational

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

NCT00475605
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
Up to 16 Years
Enrollment
8,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
198
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects

NCT01302925
View directory record Official record
Conditions
Healthy, Actinic Keratosis
Interventions
PEP005 Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01257919
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic Acid Foam, Azelaic Acid Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT01998984
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate, Placebo
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

NCT05194540
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 7, 2026, 10:19 PM EDT
Completed No phase listed Observational

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

NCT01982552
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

NCT00704262
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Treatment of Actinic Keratoses (AK) on the Face

NCT02411851
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ingenol mebutate 0.015%, dermasil lotion
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

NCT00626795
View directory record Official record
Conditions
Impetigo, Secondarily Infected Traumatic Lesions
Interventions
TD1414 2% cream, Bactroban® (mupirocin) 2% cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

NCT02549339
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 3 Interventional

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

NCT00031096
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Mobile, Alabama • Boulder, Colorado • Newnan, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

NCT05099133
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, LEO 138559 Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

NCT01947738
View directory record Official record
Conditions
Healthy
Interventions
VBY-891, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 7, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

NCT07487948
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions
Delgocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 7, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT01541553
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy, Vehicle, Ingenol metabute
Procedure · Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Fremont, California • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 7, 2026, 10:19 PM EDT